Cancer Research UK logo.
SearchDonate
  • Search

A trial comparing different chemotherapy drug combinations with or without Mylotarg for acute myeloid leukaemia (AML15)

Overview

Cancer types:

Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia

Status:

Results

Phase:

Phase 3

Details

This trial was looking at different chemotherapy plans and a type of biological therapy called gemtuzumab ozogamicin (Mylotarg) for acute myeloid leukaemia. Most of the people who took part were under the age of 60.

Please note - There is another part of this trial for people with a type of AML called acute promyelocytic leukaemia which is entered separately on our database.

Recruitment start: 15 May 2002

Recruitment end: 14 January 2009

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Alan Burnett

Supported by

Experimental Cancer Medicine Centre (ECMC)

Medical Research Council (MRC)

NIHR Clinical Research Network: Cancer

Last reviewed: 22 Aug 2013

CRUK internal database number: 217

Help and support